Abstract

Despite the high prevalence of both cervico-vaginal human papillomavirus (HPV) infection and bacterial vaginosis (BV) worldwide, their causal relationship remains unclear. While BV has been presumed to be a risk factor for HPV acquisition and related carcinogenesis for a long time, here, supported by both a large retrospective follow-up study (n = 6,085) and extensive in vivo data using the K14-HPV16 transgenic mouse model, we report a novel blueprint in which the opposite association also exists. Mechanistically, by interacting with several core members (NEMO, CK1 and β-TrCP) of both NF-κB and Wnt/β-catenin signaling pathways, we show that HPV E7 oncoprotein greatly inhibits host defense peptide expression. Physiologically secreted by the squamous mucosa lining the lower female genital tract, we demonstrate that some of these latter are fundamental factors governing host-microbial interactions. More specifically, several innate molecules down-regulated in case of HPV infection are hydrolyzed, internalized and used by the predominant Lactobacillus species as amino acid source sustaining their growth/survival. Collectively, this study reveals a new viral immune evasion strategy which, by its persistent/negative impact on lactic acid bacteria, ultimately causes the dysbiosis of vaginal microbiota.

Here, the authors show that HPV infection leads to downregulation of host mucosal innate peptides, which are in turn used by predominant Lactobacillus species as amino acid source, promoting ultimately an imbalance in the vaginal flora.

Details

Title
HPV infection alters vaginal microbiome through down-regulating host mucosal innate peptides used by Lactobacilli as amino acid sources
Author
Lebeau Alizee 1 ; Bruyere, Diane 1 ; Roncarati Patrick 1 ; Peixoto, Paul 2   VIAFID ORCID Logo  ; Hervouet, Eric 2   VIAFID ORCID Logo  ; Cobraiville Gael 3 ; Taminiau Bernard 4   VIAFID ORCID Logo  ; Masson Murielle 5   VIAFID ORCID Logo  ; Gallego, Carmen 6 ; Mazzucchelli, Gabriel 7 ; Smargiasso Nicolas 7 ; Fleron Maximilien 8 ; Baiwir Dominique 8   VIAFID ORCID Logo  ; Hendrick Elodie 1 ; Pilard Charlotte 1 ; Lerho, Thomas 1 ; Reynders Celia 1 ; Ancion, Marie 1 ; Greimers Roland 9 ; Twizere Jean-Claude 10   VIAFID ORCID Logo  ; Daube Georges 4   VIAFID ORCID Logo  ; Schlecht-Louf Geraldine 6   VIAFID ORCID Logo  ; Bachelerie Françoise 6 ; Jean-Damien, Combes 11 ; Melin Pierrette 12   VIAFID ORCID Logo  ; Fillet Marianne 3 ; Delvenne Philippe 13 ; Hubert, Pascale 1 ; Herfs, Michael 1   VIAFID ORCID Logo 

 University of Liege, Laboratory of Experimental Pathology, GIGA-Cancer, Liege, Belgium (GRID:grid.4861.b) (ISNI:0000 0001 0805 7253) 
 University of Bourgogne Franche-Comté, INSERM, EFS BFC, UMR 1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Besançon, France (GRID:grid.493090.7) (ISNI:0000 0004 4910 6615); University of Bourgogne Franche-Comté, EPIGENEXP platform, Besançon, France (GRID:grid.493090.7) (ISNI:0000 0004 4910 6615) 
 University of Liege, Laboratory for the Analysis of Medicines, Center for Interdisciplinary Research on Medicines (CIRM), Liege, Belgium (GRID:grid.4861.b) (ISNI:0000 0001 0805 7253) 
 University of Liege, Department of Food Sciences-Microbiology, Fundamental and Applied Research for Animals and Health (FARAH), Faculty of Veterinary Medicine, Liege, Belgium (GRID:grid.4861.b) (ISNI:0000 0001 0805 7253) 
 University of Strasbourg, Ecole Supérieure de Biotechnologie Strasbourg, UMR 7242, CNRS, Illkirch, France (GRID:grid.11843.3f) (ISNI:0000 0001 2157 9291) 
 University of Paris-Saclay, INSERM UMR 996, Inflammation Microbiome and Immunosurveillance, Clamart, France (GRID:grid.460789.4) (ISNI:0000 0004 4910 6535) 
 University of Liege, Laboratory of Mass Spectrometry, Department of Chemistry, Liege, Belgium (GRID:grid.4861.b) (ISNI:0000 0001 0805 7253) 
 University of Liege, Laboratory of Mass Spectrometry, Department of Chemistry, Liege, Belgium (GRID:grid.4861.b) (ISNI:0000 0001 0805 7253); University of Liege, GIGA Proteomic Facility, Liege, Belgium (GRID:grid.4861.b) (ISNI:0000 0001 0805 7253) 
 University Hospital Center of Liege, Department of Pathology, Liege, Belgium (GRID:grid.411374.4) (ISNI:0000 0000 8607 6858) 
10  University of Liege, Laboratory of Signaling and Protein Interactions, GIGA-Molecular Biology of Diseases, Liege, Belgium (GRID:grid.4861.b) (ISNI:0000 0001 0805 7253) 
11  International Agency for Research on Cancer, World Health Organization, Infections and Cancer Epidemiology Group, Lyon, France (GRID:grid.17703.32) (ISNI:0000000405980095) 
12  University Hospital Center of Liege, Department of Clinical Microbiology, Liege, Belgium (GRID:grid.411374.4) (ISNI:0000 0000 8607 6858) 
13  University of Liege, Laboratory of Experimental Pathology, GIGA-Cancer, Liege, Belgium (GRID:grid.4861.b) (ISNI:0000 0001 0805 7253); University Hospital Center of Liege, Department of Pathology, Liege, Belgium (GRID:grid.411374.4) (ISNI:0000 0000 8607 6858) 
Publication year
2022
Publication date
2022
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2634281197
Copyright
© The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.